David Baxter PhD
Late Founder
New faster acting antidepressant compounds discovered
Thursday, 6 September 2007
Studies with rats have revealed the potential in an entirely new class of antidepressants that take effect after only days of treatment versus the weeks required for current drugs. The researchers said that they hope their findings will spur development of such new antidepressant drugs so that clinical testing can begin quickly.
Guillaume Lucas and colleagues from Canada, France and Denmark published their findings in the September 6, 2007, issue of the journal Neuron.
Depression can be treated by enhancing the action of the neurotransmitter serotonin in the brain. Such neurotransmitters are the chemical signals that one neuron launches at another to trigger a nerve impulse in the target neuron. The most widely used antidepressants-called selective serotonin reuptake inhibitors (SSRIs) - work by inhibiting recycling of serotonin after a nerve impulse, increasing its concentration in the connections between neurons.
However, a different class of drugs exists that directly enhances nerve impulses of serotonin neurons. In their experiments, Lucas and colleagues tested in rats the effects of two such "serotonin receptor agonist" compounds, called RS 67333 and prucalopride, that target serotonin 5-HT4 receptors.
Current SSRI antidepressants mainly target receptors of the 5-HT1, 5-HT2 and 5-HT3 'families'.
In initial experiments, they compared the two drugs with the widely used SSRI citalopram in a test of the effectiveness of these drugs on a measure of antidepressant activity in rats. In this test, rats are forced to swim, and the time it takes for them to give up and become immobile is determined. Both of the serotonin receptor agonists strongly reduced this time of immobility, indicating an antidepressant action.
In further studies, the researchers found that only three days of treatment with the serotonin receptor agonists induced antidepressant-related changes in the brains of the animals that were only achieved after weeks of treatment with SSRIs. For example, the serotonin receptor agonists triggered changes in neuronal activity associated with antidepressant properties and also enhanced generation of new brain cells in the hippocampus-a beneficial effect of SSRIs on depression.
The researchers also found that the serotonin receptor agonists quickly and effectively alleviated symptoms of chronic depression in the rats. In one such rat model of chronic depression, mild stress has been shown to reduce intake of sugar water-a behavior alleviated by weeks of treatment with SSRIs. The researchers found that one of the serotonin receptor agonists took effect after only three days and appeared to completely alleviate the symptom after a week.
"Overall, the results presented here show a clear potential for [serotonin receptor] agonists as putative antidepressants with a rapid onset of action," wrote the researchers. "According to the different experimental models studied, they may act four to seven times more rapidly than classical [antidepressants] and possibly with greater efficacy. Presently, RS 67333 and prucalopride are virtually the only available selective [serotonin receptor] agonists that are able to cross the blood-brain barrier; we hope that this study may contribute to the development of new compounds, so that clinical trials can be conducted in the near future," they write.
In an editorial accompanying the study, Ronald S. Duman, Ph.D., from Yale University's departments of Psychiatry and Pharmacology writes, "The search for a rapid-acting antidepressant has been a subject of intense research interest for several decades. The article by Lucas and colleagues in this issue of Neuron provides compelling evidence from preclinical animal models that drugs acting at the serotonin 5-HT4 receptor could finally achieve this goal." However, he cautions that "...results from animal studies are not always predictive of therapeutic actions in humans."
Sadly, study supervisor, Dr. Guy Debonnel, a highly respected depression researcher passed away unexpectedly at the age of 57 in November, 2006 as the research was nearing its close.
Source: Lucas G, Rymar VV, Du J, Mnie-Filali O, et al. Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action. Neuron 2007 Sept 6;55:712-725 [Abstract]
Thursday, 6 September 2007
Studies with rats have revealed the potential in an entirely new class of antidepressants that take effect after only days of treatment versus the weeks required for current drugs. The researchers said that they hope their findings will spur development of such new antidepressant drugs so that clinical testing can begin quickly.
Guillaume Lucas and colleagues from Canada, France and Denmark published their findings in the September 6, 2007, issue of the journal Neuron.
Depression can be treated by enhancing the action of the neurotransmitter serotonin in the brain. Such neurotransmitters are the chemical signals that one neuron launches at another to trigger a nerve impulse in the target neuron. The most widely used antidepressants-called selective serotonin reuptake inhibitors (SSRIs) - work by inhibiting recycling of serotonin after a nerve impulse, increasing its concentration in the connections between neurons.
However, a different class of drugs exists that directly enhances nerve impulses of serotonin neurons. In their experiments, Lucas and colleagues tested in rats the effects of two such "serotonin receptor agonist" compounds, called RS 67333 and prucalopride, that target serotonin 5-HT4 receptors.
Current SSRI antidepressants mainly target receptors of the 5-HT1, 5-HT2 and 5-HT3 'families'.
In initial experiments, they compared the two drugs with the widely used SSRI citalopram in a test of the effectiveness of these drugs on a measure of antidepressant activity in rats. In this test, rats are forced to swim, and the time it takes for them to give up and become immobile is determined. Both of the serotonin receptor agonists strongly reduced this time of immobility, indicating an antidepressant action.
In further studies, the researchers found that only three days of treatment with the serotonin receptor agonists induced antidepressant-related changes in the brains of the animals that were only achieved after weeks of treatment with SSRIs. For example, the serotonin receptor agonists triggered changes in neuronal activity associated with antidepressant properties and also enhanced generation of new brain cells in the hippocampus-a beneficial effect of SSRIs on depression.
The researchers also found that the serotonin receptor agonists quickly and effectively alleviated symptoms of chronic depression in the rats. In one such rat model of chronic depression, mild stress has been shown to reduce intake of sugar water-a behavior alleviated by weeks of treatment with SSRIs. The researchers found that one of the serotonin receptor agonists took effect after only three days and appeared to completely alleviate the symptom after a week.
"Overall, the results presented here show a clear potential for [serotonin receptor] agonists as putative antidepressants with a rapid onset of action," wrote the researchers. "According to the different experimental models studied, they may act four to seven times more rapidly than classical [antidepressants] and possibly with greater efficacy. Presently, RS 67333 and prucalopride are virtually the only available selective [serotonin receptor] agonists that are able to cross the blood-brain barrier; we hope that this study may contribute to the development of new compounds, so that clinical trials can be conducted in the near future," they write.
In an editorial accompanying the study, Ronald S. Duman, Ph.D., from Yale University's departments of Psychiatry and Pharmacology writes, "The search for a rapid-acting antidepressant has been a subject of intense research interest for several decades. The article by Lucas and colleagues in this issue of Neuron provides compelling evidence from preclinical animal models that drugs acting at the serotonin 5-HT4 receptor could finally achieve this goal." However, he cautions that "...results from animal studies are not always predictive of therapeutic actions in humans."
Sadly, study supervisor, Dr. Guy Debonnel, a highly respected depression researcher passed away unexpectedly at the age of 57 in November, 2006 as the research was nearing its close.
Source: Lucas G, Rymar VV, Du J, Mnie-Filali O, et al. Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action. Neuron 2007 Sept 6;55:712-725 [Abstract]
